Detailed Instructions: In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.
Problem:SECTION 1. SHORT TITLE.

This Act may be cited as the ''Inflammatory Bowel Disease Research
Enhancement Act''.

SEC. 2. FINDINGS.

Congress makes the following findings:
(1) Crohn's disease and ulcerative colitis are serious
inflammatory diseases of the gastrointestinal tract.
(2) Crohn's disease may occur in any section of the
gastrointestinal tract but is predominately found in the lower
part of the small intestine and the large intestine. Ulcerative
colitis is characterized by inflammation and ulceration of the
innermost lining of the colon. Complete removal of the colon in
patients with ulcerative colitis can potentially alleviate and
cure symptoms.
(3) Because Crohn's disease and ulcerative colitis behave
similarly, they are collectively known as inflammatory bowel
disease. Both diseases present a variety of symptoms, including
severe diarrhea, abdominal pain with cramps, fever, and rectal
bleeding. There is no known cause of inflammatory bowel
disease, or medical cure.
(4) It is estimated that up to 1,400,000 people in the
United States suffer from inflammatory bowel disease, 30
percent of whom are diagnosed during their childhood years.
(5) Children with inflammatory bowel disease miss school
activities because of bloody diarrhea and abdominal pain, and
many adults who had onset of inflammatory bowel disease as
children had delayed puberty and impaired growth and have never
reached their full genetic growth potential.
(6) Inflammatory bowel disease patients are at high risk
for developing colorectal cancer.

SEC. 3. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
DISEASES; INFLAMMATORY BOWEL DISEASE RESEARCH EXPANSION.

Subpart 3 of part C of title IV of the Public Health Service Act
(42 U.S.C. 285c et seq.) is amended by adding at the end the following:

''SEC. 434B. INFLAMMATORY BOWEL DISEASE.

''(a) In General.--The Director of the Institute shall expand,
intensify, and coordinate the activities of the Institute with respect
to research on inflammatory bowel disease. Such research may be focused
on, but not limited to, the following areas:
''(1) Genetic research on susceptibility for inflammatory
bowel disease, including the interaction of genetic and
environmental factors in the development of the disease.
''(2) Research targeted to increase knowledge about the
causes and complications of inflammatory bowel disease in
children.
''(3) Animal model research on inflammatory bowel disease,
including genetics in animals.
''(4) Clinical inflammatory bowel disease research,
including clinical studies and treatment trials.
''(5) Expansion of the Institute's Inflammatory Bowel
Disease Centers program with a focus on pediatric research.
''(6) The training of qualified health professionals in
biomedical research focused on inflammatory bowel disease,
including pediatric investigators.
''(7) Other research priorities identified by the
scientific agendas 'Challenges in Inflammatory Bowel Disease
Research' (Crohn's and Colitis Foundation of America) and
'Chronic Inflammatory Bowel Disease' (North American Society
for Pediatric Gastroenterology, Hepatology and Nutrition).
''(b) Authorization of Appropriations.--To carry out subsection
(a), there are authorized to be appropriated $80,000,000 for fiscal
year 2008, $90,000,000 for fiscal year 2009, and $100,000,000 for
fiscal year 2010.''.

SEC. 4. CENTERS FOR DISEASE CONTROL AND PREVENTION; EXPANSION OF
INFLAMMATORY BOWEL DISEASE EPIDEMIOLOGY PROGRAM.

Part A of title III of the Public Health Service Act (42 U.S.C. 241
et seq.) is amended by adding at the end the following:

''SEC. 310A. CENTERS FOR DISEASE CONTROL AND PREVENTION; EXPANSION OF
INFLAMMATORY BOWEL DISEASE EPIDEMIOLOGY PROGRAM.

''(a) In General.--Not later than 1 year after the date of
enactment of this Act, the Director of the Centers for Disease Control
and Prevention shall expand the Inflammatory Bowel Disease Epidemiology
Program within the National Center for Chronic Disease Prevention and
Health Promotion to include additional studies focused on--
''(1) the incidence and prevalence of pediatric
inflammatory bowel disease in the United States;
''(2) genetic and environmental factors associated with
pediatric inflammatory bowel disease;
''(3) age, race or ethnicity, gender, and family history of
individuals diagnosed with pediatric inflammatory bowel
disease; and
''(4) treatment approaches and outcomes in pediatric
inflammatory bowel disease.
''(b) Consultation.--The Director shall carry out subsection (a) in
consultation with a national voluntary patient organization with
experience serving the population of individuals with pediatric
inflammatory bowel disease and organizations representing physicians
and other health professionals specializing in the treatment of such
populations.
''(c) Authorization of Appropriations.--To carry out this section,
there are authorized to be appropriated $5,000,000 for fiscal year
2008, and such sums as may be necessary for each of fiscal years 2009
and 2010.''.
Solution:
Inflammatory Bowel Disease Research Enhancement Act - Requires the Director of the National Institute of Diabetes and Digestive and Kidney Diseases to expand, intensify, and coordinate the Institute's research activities on inflammatory bowel disease, with a focus on: (1) genetic research on susceptibility for inflammatory bowel disease; (2) research targeted to increase knowledge about the causes and complications of inflammatory bowel disease in children; (3) animal model research; (4) clinical research; (5) expansion of the Institute's Inflammatory Bowel Disease Centers program with a focus on pediatric research; (6) training of qualified health professionals in biomedical research focused on inflammatory bowel disease; and (7) other research priorities identified in specified scientific agendas.

Requires the Director of the Centers for Disease Control and Prevention (CDC) to expand the Inflammatory Bowel Disease Epidemiology Program to include additional studies focused on: (1) the incidence and prevalence of pediatric inflammatory bowel disease in the United States; (2) genetic and environmental factors associated with the disease; (3) age, race or ethnicity, gender, and family history of individuals diagnosed with the disease; and (4) treatment approaches and outcomes.